Stock CMRX CHIMERIX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Chimerix, Inc.

Equities

CMRX

US16934W1062

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.8999 USD +1.00% Intraday chart for Chimerix, Inc. +1.75% -6.50%
Mar. 21 Chimerix Appoints Marc D. Kozin to Board of Directors CI
Feb. 29 Transcript : Chimerix, Inc., Q4 2023 Earnings Call, Feb 29, 2024

Evolution of the average Target Price on Chimerix, Inc.

Price target over the last 5 years

History of analyst recommendation changes

2ce184e6aace9e265ded.U5awyos5MjGQl48Plwxw_fN0uNGUu8bIA_tZ-PHu6WQ.OPje-_59ZEP04_1Lw0IjzoEb3qDtjayvSr8vqrS_uBUm8Imf4QFICP_e5A~207953a32ff4eb0548ef6093c4c117a4

Analyst Recommendations on Chimerix, Inc.

Baird Initiates Chimerix at Outperform With $7 Price Target MT
Capital One Starts Chimerix at Overweight With $7 Price Target MT
Wedbush Cuts Price Target on Chimerix to $6 From $8, Citing ONC201 Estimated Launch, Keeps Outperform Rating MT
HC Wainwright Adjusts Price Target on Chimerix to $11 From $24, Reiterates Buy Rating MT
Cowen Lowers Price Target for Chimerix to $10 From $18, Maintains Outperform Rating MT
Wedbush Adjusts Chimerix Price Target to $8 From $14, Maintains Outperform Rating MT
HC Wainwright Adjusts Chimerix's Price Target to $24 From $21, Keeps Buy Rating MT
Wedbush Trims Price Target on Chimerix to $14 From $15, Keeps Outperform Rating MT
Wedbush Trims Price Target for Chimerix to $14 From $15, Maintains Outperform Rating MT
HC Wainwright Adjusts Chimerix PT to $21 From $19, Maintains Buy Rating MT
Chimerix Says ONC201 Glioma Treatment Candidate Showed 20% Response Rate in Patient Sample From Studies MT
CHIMERIX : HC Wainwright Adjusts Chimerix' Price Target to $19 From $18, Keeps Buy Rating MT
CHIMERIX : Wedbush Adjusts Price Target for Chimerix to $15 From $14, Maintains Outperform Rating MT
CHIMERIX : Maxim Group Initiates Chimerix at Buy Rating With $20 Price Target MT
CHIMERIX : Jefferies Starts Chimerix at Buy With $21 Price Target MT
CHIMERIX : Wedbush Starts Chimerix at Outperform With $14 Price Target MT
CHIMERIX : HC Wainwright Adjusts Chimerix's Price Target to $16 From $7, Keeps at Buy MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
0.8999 USD
Average target price
7 USD
Spread / Average Target
+677.86%
High Price Target
11 USD
Spread / Highest target
+1,122.36%
Low Price Target
5 USD
Spread / Lowest Target
+455.62%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Chimerix, Inc.

Baird
Capital One Securities
Wedbush
HC Wainwright
Cowen
Maxim
Jefferies & Co.

Ratings for Chimerix, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CMRX Stock
  4. Consensus Chimerix, Inc.